PD Dr. med. Mohammed Banat (Bonn / DE), Dr. med. Anna Laura Potthoff (Bonn / DE), Dr. med. Motaz Hamed (Bonn / DE), Dr. med. Tim Lampmann (Bonn / DE), Dr. med. Harun Asoglu (Bonn / DE), Prof. Dr. med. Hartmut Vatter (Bonn / DE), PD Dr. med. Matthias Schneider (Bonn / DE)
Abstract-Text (inkl. Referenzen und Bildunterschriften)
Purpose
Patients with spinal metastasis (SM) from solid tumors are often in an advanced stage of cancer. SM may to arise during a known oncological disease (metachronous SM) or be the primary manifestation of previously unknown cancer (synchronous SM). The time of diagnosis might decisively impact patient prognosis and further treatment stratification. In the present study, we analyzed the prognostic impact of synchronous versus (vs.) metachronous SM occurrence following resection of BM.
Methods
Between 2015 and 2020, 211 patients were surgically treated for SM at the authors' neuro-oncological center. Survival stratification calculated from the day of neurosurgical resection was performed for synchronous vs. metachronous SM diagnosis.
Results
Lung cancer was the most common tumor entity of primary site (23%) followed by prostate (21%) and breast cancer (11.3%). Synchronous SM occurrence was present in 97 patients (46%), metachronous SM occurrence was present in 114 patients (54%). The median overall survival for patients with synchronous SM diagnosis was 13.5 months compared to 13 months for patients with metachronous SM diagnosis (p=0.74).
Conclusions
The present study indicates that time of SM diagnosis (synchronous vs. metachronous) does not significantly impact patient survival following surgical therapy of SM. These results suggest that the indication for neurosurgical therapy should be made regardless of a synchronous or a metachronous time of SM occurrence.